title: Current physiologic pacemakers: a serious problem with a new device.
abstract: Twenty adults underwent implantation of an automatic (DDD) pacemaker (Medtronic model 7000, Versatrax I) for treatment of symptomatic bradyarrhythmias. Only 9 patients had optimal DDD mode pacing during 78 paced months. In 3 patients, the DDD mode was changed to atrioventricular (AV) sequential (DVI) early because of risk imposed by sustained tachycardia upon underlying myocardial ischemia. The remaining 8 had had tachycardia due to pacemaker reentry, and 7 had neurologic and cardiovascular symptoms. DDD pacing was abandoned in 5 when reentry could not be interrupted by digitalis administration or reprogramming. Three continue to be paced in DDD mode despite intermittent reentrant tachycardias, with digitalis diminishing episodes of reentry in only 1. Mean ventriculoatrial conduction time was 229 +/- 34 ms. Reentrant pacemaker tachycardia developed in 7 of 12 with normal or nearly normal AV conduction, but in only 1 of 5 with complete heart block. Preimplantation electrophysiologic study did not reliably detect and initial postoperative Holter monitoring did not predict reentrant tachycardia. The risk of reentry caused by a short, fixed atrial refractory period combined with the high occurrence of slow retrograde AV conduction, particularly in patients with normal or nearly normal anterograde conduction, renders the Versatrax I and other similar pacemakers unsuitable for DDD mode pacing in many patients.
mesh_terms: D001919:Bradycardia / Q000628:therapy*; D004071:Digitalis Glycosides / Q000627:therapeutic use; D004562:Electrocardiography; D006329:Heart Conduction System / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010138:Pacemaker, Artificial / Q000009:adverse effects*; D013610:Tachycardia / Q000188:drug therapy / Q000209:etiology*
chemical_list: D004071:Digitalis Glycosides